Viking Therapeutics Inc buy stratec
Summary
This prediction ended on 18.09.18 with a price of €20.14. The BUY prediction by stratec for Viking Therapeutics Inc saw massive gains of 458.13%. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Viking Therapeutics Inc | -3.576% | -3.576% | 254.698% | 1363.972% |
iShares Core DAX® | 1.851% | 5.158% | 17.711% | 19.954% |
iShares Nasdaq 100 | 1.573% | 2.589% | 39.053% | 56.636% |
iShares Nikkei 225® | -0.412% | -2.857% | 13.501% | 7.721% |
iShares S&P 500 | 1.128% | 2.485% | 29.871% | 47.507% |
Comments by stratec for this prediction
In the thread Viking Therapeutics Inc diskutieren
Viking Therapeutics is undervalued
At the end of November the company announced positive results from a 12-week mid-stage study evaluating VK5211 in patients who recently suffered a hip fracture. The drug candidate is an orally
available, non-steroidal selective androgen receptor modulator (SARM) which was created to stimulate bone and muscle formation with a reduction of activity in peripheral tissues.
Jay Magaziner, PhD, MSHyg, Professor and Chair, Department of Epidemiology and Public Health at the University of Maryland School of Medicine, had the following commentary:
The degree of improvement in lean body mass in this group of older persons who are prone to losing muscle is impressive. Having a drug like this available that can be taken easily and safely soon after hip fracture would provide a valuable adjunct to other therapeutic strategies such as physical therapy and a protein-rich diet to boost patients' chances for resuming usual activities.
In the future one can expect further updates on endpoints including exploratory measures of functional performance. Considering that the drug candidate could have blockbuster potential and even if peak sales were $500 million to be ultra conservative, based on this one candidate alone it would seem the company is undervalued. According to the company there are around 300,000 patients per year in the United States for the target indication.
Stopped prediction by stratec for Viking Therapeutics Inc
Viking Therapeutics Inc
25.09.18
04.11.21
05.11.21